Navigation Links
TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today promising results of its phase I clinical trials demonstrating the safety and pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the treatment of osteoporosis.

A seven day, repeated dose application, parallel group study was conducted on 48 healthy, elderly, post-menopausal women. The study was designed to evaluate the safety and tolerability of ascending multiple doses of hPTH (1-34) patches and to compare the pharmacokinetic profiles of the transdermally delivered doses of hPTH (1-34) with that of FORTEO(R) administered subcutaneously.

Transdermal hPTH (1-34) was delivered using TransPharma's fully integrated product, which is comprised of a proprietary pocket-sized device and 1 cm(2) dry hPTH (1-34) patch with demonstrated room-temperature stability.

Once-daily transdermal delivery of all doses tested in this trial demonstrated a safety profile similar to the one observed in the FORTEO(R) subcutaneous injection. All safety parameters (including calcium and phosphorous) of the different transdermal doses were within the normal range. Furthermore, all ViaDerm-hPTH (1-34) doses were very well tolerated by participants.

Pharmacokinetic profiles of hPTH (1-34) in the first and seventh day were similar, showing no accumulation of hPTH (1-34) levels and no deterioration in hPTH (1-34) systemic levels. These findings demonstrate the ViaDerm-hPTH (1-34) product's ability to provide reproducible drug levels resulting in excellent inter- and intra-participant variability.

Transdermally delivered hPTH (1-34) of all doses showed desirable peak profiles with relative bioavailability of approximately 40%. This bioavailability is amo ng the highest reported bioavailability of alternative drug delivery routes to subcutaneous administration.

"We are very excited by the results of our phase I studies. The promising findings are further validation that the ViaDerm-hPTH (1-34) product can provide a viable alternative administration route for hPTH (1-34) for women suffering from osteoporosis, which would alleviate the pain and inconvenience associated with their current treatment, thereby increasing compliance," said Dr. Daphna Heffetz, CEO of TransPharma Medical Ltd. "Strongly encouraged by the results of our series of phase I studies, which included a total of 66 post-menopausal healthy women volunteers, we plan to initiate a phase II study of the ViaDerm-hPTH (1-34) product, bringing this potential product to an advanced clinical stage before seeking a partner to take it to market," Dr. Heffetz added.

About Osteoporosis

hPTH (1-34) is currently the only osteoporosis drug to possess anabolic properties. According to the National Osteoporosis Foundation, approximately 10 million people in the US currently suffer from osteoporosis and another 34 million are estimated to have low bone mass, placing them at increased risk for the disease. Over the next five years, the number of people suffering from osteoporosis is expected to reach 52 million, creating a $10.4 billion market by 2011.

About the ViaDerm System

TransPharma's ViaDerm drug delivery system incorporates a handheld electronic control unit combined with a drug patch. The system provides a cost-effective, easy-to-use, self-administered solution that enables the safe, reproducible and accurate delivery of a wide variety of product candidates, including hydrophilic small molecules, peptides and proteins.

About TransPharma Medical

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietar y active transdermal drug delivery technology. TransPharma aims to develop multiple drug products through strategic partnerships with leading pharmaceutical companies and through independent product development. For more information, visit the Company's website at www.transpharma-medical.com.

Contact

TransPharma Medical Ltd.
Naomi Rabbie, +972-8-915-2201 ext. 251
Marketing Manager
naomir@transpharma.co.il


'"/>




Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
9. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
10. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 5, 2016  Replikins Ltd. today reported initial promising results in animal trials of ... http://photos.prnewswire.com/prnh/20160505/364345 ... ... ... Zika specimens recorded on Pubmed. The analysis identified the highest gene Replikin Counts in ...
(Date:5/5/2016)... -- Endo International plc (NASDAQ: ENDP ) ... , President, U.S. Branded Pharmaceuticals, has decided to ... of a successor. Mr. Lortie joined Endo in ... responsibility for all strategic, commercial and operational functions, ... commercial operations, managed markets, manufacturing, supply chain and ...
(Date:5/5/2016)... , May 5, 2016 Endo International plc (NASDAQ: ... of Douglas S. Ingram , former president of Allergan, ... Todd B. Sisitsky , managing partner of TPG Capital, to ... "Endo recently embarked on ... enhance and expand the Board,s capabilities. Doug and Todd are ...
Breaking Medicine Technology:
(Date:5/5/2016)... Tucson, AZ (PRWEB) , ... May 05, 2016 , ... ... more attention being paid to the impact our aging population has on communities and ... help aging adults plan for and face age-related challenges. , Aging Life Care ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pivot Point Consulting ... gold standard KLAS Performance Report, Epic Consulting 2016 - Which Firms ... specialize in consulting services for electronic health record (EHR) solutions from Epic ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono ... today announced a development collaboration with the Australian critical medicine company, Phebra ... as schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited to ... public stakeholder review. The stakeholder review is an important opportunity for interested parties to ... delivers value to the wool industry., The RWS is intended to be a global ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous ... to all vaping products that entered the market since February 15, 2007. That ...
Breaking Medicine News(10 mins):